Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Tesla solar panels ignited at an Amazon warehouse in Redlands, California in June 2018, Bloomberg reports. The news comes days after Walmart sued Tesla for at least 7 fires...Technologyread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
Justin Gover, the CEO of GW Pharmaceuticals, told CNBC his company's new drug will pave the way for other medications derived from marijuana.
On Monday, the Food and Drug Administration approved the company's new epilepsy drug, Epidiolex, the first cannabis-based drug the U.S. regulator has approved.
"This is an approval, not just a landmark for Epidiolex and for patients who may benefit from this specific medication, but also a strong belief from this company that cannabinoids have a bright future in the form of other drug candidates derived from the cannabis plant across a range of other disease areas," Gover said Tuesday on "Power Lunch. "
The medication is made from cannabidiol (CBD), one of hundreds of molecules found in marijuana plants. However, it is not known to produce a high. In fact, the drug concoction contains less than 0.1 percent of tetrahydrocannabinol (THC), the substance that induces a high.
Epidiolex has been developed to treat seizures in people 2 years and older with Dravet Syndrome and Lennox-Gastaut Syndrome, two rare forms of epilepsy that begin in childhood. Both diseases have high rates of mortality and few alternative options for treatment.
Gover said GW has been conducting research on cannabinoids, a group of closely related compounds that include cannabinol and the active constituents of cannabis, for about 10 years. The company is continuing to do research on other cannabinoid drug candidates in a range of disease areas, particularly within neurology.
However, since the U.S. government classifies marijuana as a Schedule 1 substance, meaning it has high potential for abuse, the medicine must also be approved by the Drug Enforcement Administration.
The DEA is evaluating the drug to determine if it has medical properties appropriate for selling. The DEA has 90 days to complete this process, Gover said.
The CEO said he doesn't anticipate any delays and that GW is planning to launch the medication as early as this fall. No price has been set for the drug.
Cowen analysts said if Epidiolex is approved, sales could reach $1.3 billion annually by 2022.
— Reuters contributed to this report.